EICHORCondition: End Stage Renal Disease · Sponsor: Xeltis
A multi-center, prospective, single-arm, non-randomized, staged, pivotal clinical study to evaluate the safety and performance of the aXess graft in subjects aged 18 and above, diagnosed with end-stage kidney disease, and possessing an estimated glomerular filtration rate (eGFR) less than 20 ml/min, who intend to undergo hemodialysis but are considered unsuitable candidates for fistula creation by the investigating surgeon.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| AKDHC Medical Research Services, LLC | Phoenix, Arizona, United States | — |
| AKDHC Medical Research Services, LLC | Tuscon, Arizona, United States | — |
| Sarasota Memorial Hospital | Sarasota, Florida, United States | — |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | — |
| Greenwood Leflore Hospital | Greenwood, Mississippi, United States | — |
| Surgical Specialists of Charlotte | Charlotte, North Carolina, United States | — |
| Flow Vascular, Surgery Specialty Hospitals of America | Pasadena, Texas, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06494631